Back to Search
Start Over
A prospective evaluation of serum kynurenine metabolites and risk of pancreatic cancer.
- Source :
- PLoS ONE; 5/7/2018, Vol. 13 Issue 5, p1-13, 13p
- Publication Year :
- 2018
-
Abstract
- Background: Serum pyridoxal 5’-phosphate (PLP), the active form of vitamin B<subscript>6</subscript>, is associated with reduced risk of pancreatic cancer. Data on functional measures of vitamin B<subscript>6</subscript> status and risk of pancreatic cancer is lacking. Methods: A nested case-control study involving 187 incident cases of pancreatic cancer and 362 individually matched controls were conducted within two prospective cohorts to evaluate the associations between kynurenine metabolites in pre-diagnostic serum samples and risk of pancreatic cancer. Results: Higher serum concentrations of 3-hydroxyanthranilic acid (HAA) and the HAA:3-hydroxykynurenine (HK) ratio (a measure for in vivo functional status of PLP) were significantly associated with reduced risk of pancreatic cancer. Compared with the lowest tertile, odds ratios (95% confidence intervals) of pancreatic cancer for the highest tertile was 0.62 (0.39, 1.01) for HAA, and 0.59 (0.35–0.98) for the HAA:HK ratio, after adjustment for potential confounders and serum PLP (both Ps for trend<0.05). The kynurenine:tryptophan ratio or neopterin was not significantly associated with pancreatic cancer risk. Conclusions: The inverse association between HAA or the HAA:HK ratio and risk of pancreatic cancer supports the notion that functional status of PLP may be a more important measure than circulating PLP alone for the development of pancreatic cancer. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 19326203
- Volume :
- 13
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- PLoS ONE
- Publication Type :
- Academic Journal
- Accession number :
- 129480420
- Full Text :
- https://doi.org/10.1371/journal.pone.0196465